| Document |
Document Title |
|
WO/2013/019926A1 |
The invention provides a method of enhancing the efficacy of antibiotic treatment of tuberculosis, trypanosomiasis, leprosy, and leishmaniasis involving co-administering to a mammal undergoing antibiotic treatment therapeutically effecti...
|
|
WO/2013/017678A1 |
This invention relates to novel spiroindoline compounds of formula (I) that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections...
|
|
WO/2013/014445A1 |
Deoxythymidine derivatives according to formula (I) are disclosed. wherein: X may be O or S; and R1, R2, R3, R4 and R5 may each be independently selected from H, halo, C1-C6 alkyl, C1-C6 haloalkyl, nitro, phenyl, heteroaryl, substituted ...
|
|
WO/2013/013603A1 |
A livestock intestinal sustained-release anthelmintic comprising a medicament particle (3), an intermediate layer (2), and a surface layer (1). The intermediate layer (2) covers the exterior surface of the medicament particle (3), while ...
|
|
WO/2013/015429A1 |
The present invention provides an animal ectoparasite-controlling agent and a method for preventing or treating infection in animals caused by parasites by using the controlling agent. An animal ectoparasite-controlling agent exhibiting ...
|
|
WO/2013/014059A1 |
The invention relates to prodrug derivatives of pentamidine, to the use thereof for the treatment and/or prophylaxis of diseases, in particular tumours, leishmaniasis, trypanosomiasis, Pneumocystis carinii pneumonia (PcP), and malaria.
|
|
WO/2013/010238A1 |
The proposed innovation relates to a pharmaceutical composition containing amphotericin B, nitrochalcone (CH8) or glucantime encapsulated in biodegradable, slow-release polymer microparticles, to the method of encapsulating the pharmaceu...
|
|
WO/2013/011247A1 |
The present invention relates to novel compositions and methods for immunizing a host against malaria using a Plasmodium parasite which has been genetically attenuated by inactivating the function of the hmgb2 gene.
|
|
WO/2013/007663A1 |
The invention relates to compounds that act as selective glycogen synthase kinase 3 (GSK-3) ligands and can be used for the treatment of GSK-3-mediated diseases. The compounds of the invention act as glycogen synthase kinase 3 (GSK-3) in...
|
|
WO/2013/008218A1 |
The field of the invention relates to stable oral dosage forms comprising, (a) cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methylpropyl) amino]carbonyl]-methyl]-l',2',4'-trioxaspiro[4.5]decane hydrogen maleate (Active compound I); (b) p...
|
|
WO/2013/006956A1 |
The present disclosure provides a modified cecropin protein comprising a cecropin or a variant thereof fused to a hydrophilic tail lacking a C-terminal glycine. The present disclosure also provides pharmaceutical compositions, methods an...
|
|
WO/2013/004032A1 |
Disclosed in the present invention is a composition for treating chicken intestine toxicity syndrome and preparation method thereof, which are intended to provide a composition that can treat chicken intestine toxicity syndrome both supe...
|
|
WO/2013/004116A1 |
The present invention relates to a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1 is H, hydroxyl or methoxyl; R2 is hydroxyl; R3 is heteroatom-substituted or unsubstituted organi...
|
|
WO/2013/006024A1 |
An in vitro method of diagnosing and/or treating at least one subject as having or as being at risk of having Entamoeba histolytica (E. histolytica) infection, the method comprising detecting the presence of at least one E. histolytica p...
|
|
WO/2013/003505A1 |
The subject matter disclosed herein is directed to amido-pyridyl ether compounds of formula I: wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, Ra, a, b and d are as described herein, compositions comprising the compounds of formul...
|
|
WO/2012/176131A1 |
Disclosed are compositions and methods that in some embodiments are useful in the treatment of pediculosis.
|
|
WO/2012/177151A1 |
This invention relates to a veterinary antiparasitic solubilised composition including a macrocyclic lactone or a pharmaceutically equivalent salt thereof, and levamisole or a pharmaceutically equivalent salt thereof, characterised in th...
|
|
WO/2012/175659A1 |
The present invention relates to N-acetyl cysteine and to a composition comprising N-acetyl cysteine for use in the restoration of the vaginal ecosystem and/or in the treatment of vaginal pathologies characterised in that the administrat...
|
|
WO/2012/174253A1 |
A composition and process for generating an anthraquinone rich aloe product from aloe leaves comprising the steps of: removing one or more rind parts from the aloe leaves comprising a top rind, a bottom rind, or both by filleting the alo...
|
|
WO/2012/170125A2 |
The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptid...
|
|
WO/2012/167368A1 |
The present invention provides for metal chelating compositions which are soluble in aqueous media. The present invention also provides chelating compositions that possess acceptable iron sequestering strengths and are able to present a ...
|
|
WO/2012/162731A1 |
An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoite...
|
|
WO/2012/163948A1 |
The present invention provides a combination product comprising a component A and a component B, wherein component A is a compound of formula (I) wherein A1, A2, L, p, R1, R2, R3, R4 and R5 are as defined in claim 1 and component B is a ...
|
|
WO/2012/158413A2 |
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y-B moiety and the NH-C(...
|
|
WO/2012/151636A1 |
The present invention relates generally to antibodies and fragments thereof which are capable of specifically binding apicomplexan actin. The invention also relates to an epitope of apicomplexan actin which can be used to raise such anti...
|
|
WO/2012/150866A1 |
The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, an...
|
|
WO/2012/150340A1 |
The present invention relates to compounds according to the general formula (1) for use in the therapeutic or prophylactic treatment of filariasis, a nematicidal composition comprising as an active ingredient a compound according to the ...
|
|
WO/2012/150577A1 |
The invention relates to novel compounds responding to the following formula (I) or a pharmaceutically acceptable salt thereof, for use as medicaments, and in particular as medicaments for the prevention and/or the treatment of parasitic...
|
|
WO/2012/145355A1 |
The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological salt concentrations and/or physiological temperatures and as a second component one o...
|
|
WO/2012/142575A2 |
Anilide derivatives of the natural trioxane artemisinin were prepared and evaluated for antimalarial efficacy in Plasmodium berghei-infected mice. Selected anilides derivatives administered orally as one single-digit dose combined with m...
|
|
WO/2012/142457A2 |
The present invention relates to a macrolactam compound, and methods for treating a subject with malaria using the macrolactam compound, represented by the following structural formula (l), wherein the values and preferred values of the ...
|
|
WO/2012/139190A1 |
The present invention describes multilayered devices for the controlled release of volatile liquid substances and the production thereof. The multilayered films are formed by three layers of natural, biodegradable polymer (chitosan), the...
|
|
WO/2012/136724A1 |
Substituted imine compounds of formula (I), wherein D is C(R2)=N∼Z-R1 or C(=Y1)NRAY2RB and the other symbols have the meanings given in the description, their N-oxides and salts are useful for combating animal pests.
|
|
WO/2012/131010A1 |
Naphthoquinones, azanaphthoquinones and benxanthones, their process of synthesis and their use as antimalarial or antischistosomal agents.
|
|
WO/2012/131645A1 |
The present invention in an embodiment provides herbal compositions for treatment or prevention of ectoparasitic infestation. The present invention also provides for the methods of preparation and various forms of administration of the s...
|
|
WO/2012/131643A1 |
The present invention in a preferred embodiment provides for herbal compositions for treatment or prevention of gastrointestinal disorders. The present invention also provides for the methods of preparation and various forms of administr...
|
|
WO/2012/131468A1 |
This invention relates to the discovery of novel forms of Compound 1, including solvates, hydrates, and other crystalline forms. These novel forms of Compound 1 may impart advantages in pharmaceutical formulations incorporating them, inc...
|
|
WO/2012/131413A1 |
This invention relates to the discovery of novel forms of Compound 1, including solvates, hydrates, and other crystalline forms. These novel forms of Compound 1 may impart advantages in pharmaceutical formulations incorporating them, inc...
|
|
WO/2011/117346A9 |
The invention relates to a synergistic composition for controlling endoparasites in and on animals, which comprises a combination of (A) a compound of formula (I) and (B) abamectin. The compositions are useful in the control of endoparas...
|
|
WO/2012/134591A2 |
The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against Plasmodium falciparum. The inventive antigens were identified by their asso...
|
|
WO/2012/131731A1 |
The present invention relates to a formulation to treat coccidiosis. More particularly, present invention relates to a formulation prepared from Allium Odorum, Allium sativum, Tinospora cordifolia, Adhatoda vasica and Tridax procumbens t...
|
|
WO/2012/131721A1 |
A herbal composition for treatment of Filariasis. The said composition comprising predefined amount of Anthocephalus cadamba, predefined amount of Datura metel and predefined amount of mustard oil. The method for the preparation of said ...
|
|
WO/2012/127212A1 |
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, (Formula (I)) wherein: R1 is -(CH2)nNR3R4, -OR5 or -(CH2)n-heterocycloalkyl, wherein said heterocycloalkyl grou...
|
|
WO/2012/119212A1 |
The present invention relates to the synthesis and structural identification of new thiazolidine and imidazolidine compounds with trypanocidal activity, and to the therapeutic use thereof as drugs against Chagas disease.
|
|
WO/2012/118139A1 |
An internal parasiticide having a carboxamide derivative represented by formula (I) or a salt thereof as an active ingredient and a method for controlling internal parasites characterized in that said parasiticide is given orally or pare...
|
|
WO/2012/117048A1 |
The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infe...
|
|
WO/2012/116246A2 |
This document discloses pesticidal molecules having the following formula ("Formula One"): and processes related thereto.
|
|
WO/2012/108511A1 |
Provided is a novel pest control agent, particularly an insecticide or a miticide. A pyrazole derivative represented by general formula (1) and a pest control agent. In formula (1), A1 represents -N(O)m2 or -CR1; R1, R3, and R4 each inde...
|
|
WO/2012/107532A1 |
The present invention is intended to provide new antimalarial compounds with a strong antimalarial activity as well as antibacterial activity with few neurological side effects and a new enantioselective pathway to mefloquine amino-analo...
|
|
WO/2012/107585A1 |
The present invention relates to a particular solvent system including at least 35% dimethylsulfoxide (DMSO) for preparing a veterinary composition for topical application for controlling parasites in domestic animals. The topical compos...
|
